This industry profile provides a five-year forecast for Canada’s pharmaceutical products industry.
Canadian Industrial Profile: Pharmaceutical Products—Winter 2018
Canadian Industrial Profile: Pharmaceutical Products—Winter 2018
Industry Economic Analysis
$675.00
Demographics—Canada’s rapidly aging population will continue to drive strong demand for pharmaceutical products.
Bill C-30 Patent Terms—Canadian original-product manufacturers were granted an extension on patent terms when Bill C-30 (tied to the Comprehensive and Economic Trade Agreement, or CETA) came into force in September 2017. This will slow the introduction of generics into the market, benefiting holders of patented drugs.
NAFTA—More than 70 per cent of the industry’s exports are destined for the United States. Should the renegotiation of NAFTA result in curtailed access to that key market, the industry’s prospects would be significantly dampened.
Customers Who Downloaded This Also Liked
14 min read
18 min read
Require an accessible version of this research?
Upon request, Signal49 Research offers accessible versions of research. Please contact us to request your accessible version.
Learn more about our accessibility policies.
Effective January 26, 2026, AERIC Inc./Signal49 Research discontinued use of ‘The Conference Board of Canada’ name, logo and branding, which had been used by AERIC Inc./Signal49 Research under license from The Conference Board, Inc. The Conference Board, Inc. and its licensees, which are not affiliated with Signal49 Research, own all right, title and interest in THE CONFERENCE BOARD name and trademarks in Canada and have the exclusive right to their use in Canada since January 26, 2026.
